TraceLink CEO to Discuss Serialization, Global Networking and the Internet of Things in LogiPharma Keynote


NORTH READING, MA--(Marketwired - Sep 17, 2015) - TraceLink Inc., the world's largest track and trace network for connecting the Life Sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace, today announced that Shabbir Dahod, president and CEO, will deliver a keynote address at LogiPharma, one of the largest global end-to-end supply chain events to be held at the Westin Princeton in New Jersey on September 28-30. During the keynote, Dahod will highlight the vision, integrated platform requirements, and long-term opportunities for a globally connected supply network that links business processes, big data, and pharmaceutical products with patient safety and healthcare initiatives. He will share customer-led insights that have enabled multiple enterprises to achieve complex compliance initiatives on a global scale, and also reveal the most common challenges that life sciences companies face in driving lasting economic value from track and trace initiatives.

"The life sciences supply chain is at a tipping point, with new and emerging track and trace regulations driving transformative changes to critical business processes and infrastructure requirements," said Dahod, who for the past decade has been directly involved in the development of compliance standards and global pharmaceutical traceability solutions. "Implementing serialization across global operations calls for new thinking about platforms that can not only deliver massive data and processing elasticity, but network connectivity and supply chain interoperability that links businesses together to advance the value of the pharmaceutical ecosystem as a whole. I'm excited to share insights with this year's LogiPharma attendees and to discuss how the intersection of connected businesses, devices and people is advancing the Internet of Things in life sciences -- and delivering historic improvements to product integrity, operational efficiency, global commerce, and patient care."

Dahod's keynote entitled, "Serialization, Global Networking, and the Internet of Things for Life Sciences," will take place on Monday, September 28 at 11:20am EDT as part of the LogiPharma conference theme, New Ways of Thinking and Operating to Drive Business Value. Attendees can also meet with TraceLink in Booth 5 of Ballroom A-D, where the company will be showcasing the Life Sciences Cloud, the only track and trace platform used by pharmaceutical companies to achieve compliance in global markets that comprise 75 percent of the world's drug supply.

To learn more about the Life Sciences Cloud and how to build a flexible, cost-effective global serialization, track and trace, and reporting platform, visit www.tracelink.com.

About TraceLink
TraceLink is the world's largest track and trace network for connecting the Life Sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace. Leading businesses, including 16 of the top-20 global pharmaceutical companies, trust the TraceLink Life Sciences Cloud to deliver complete global connectivity, visibility and traceability of pharmaceuticals from ingredient to patient. A single point and click connection to the Life Sciences Cloud creates a supply chain control tower that delivers the information, insight and collaboration needed to improve performance and reduce risk across global supply, manufacturing and distribution operations. Winner of numerous industry awards including the Amazon AWS Global Start-Up Challenge Grand Prize and the Edison Award for Innovation in Health Management, the TraceLink Life Sciences Cloud is used by businesses across the globe to meet strategic goals in ensuring global compliance, fighting drug counterfeiting, improving on-time and in-full delivery, protecting product quality and reducing operational cost. For more information on TraceLink and our solutions, visit www.tracelink.com or follow us on LinkedIn, Twitter and Facebook.

TraceLink is funded by FirstMark Capital, Volition Capital and Fidelity Biosciences.

Contact Information:

Media Contact:
Laura MacSweeney
Red Javelin Communications
(781) 395-6420